NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

RAPT Therapeutics Inc (RAPT) Stock Analysis

RAPT Therapeutics Inc (RAPT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RAPT

$58.01

$0.00 (0.00%)

Last trade March 6, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RAPT with… →

RAPT Key Statistics

As of Mar 6, 2026
Trading
Open
$58.01
Previous Close
$58.01
52-Week Range
5.67–58.02
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.44
Valuation
Market Cap
$1.68B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−11.66
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+547.38%
Dividend and dates
Avg Volume
2.40M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RAPT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+71.26%
2025+167.96%
2024 (partial year)+95.54%

As of March 6, 2026.

RAPT Valuation vs Biotechnology Median

Median of 656 stocks
MetricRAPTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values RAPT Therapeutics Inc (RAPT) at $1.68B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 60.

The 52-week range on file runs from $5.67 to $58.02. RAPT last closed at $58.01 on March 6, 2026. The close was unchanged from the previous session. The latest close sits 923.88% above that 52-week low.

Financial Health

The reported profit margin is 0%. Earnings per share on a trailing basis come to −11.66.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned +547.38%. The reported beta is 0.44. Annualized volatility over the trailing 1 year is 119.5%.

Growth & Income

The record shows no dividend for RAPT.

The record holds one complete calendar year, 2025, which returned +167.96%. So far in 2026 the price is +71.26%.

Peer Comparison

RAPT Therapeutics Inc (RAPT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
RAPT Therapeutics Inc RAPT $1.68B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. RAPT Therapeutics Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of March 6, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About RAPT Therapeutics Inc

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.

Visit website →